Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986875 | 0.87 | RAF1 (0.45) | RAF1BRAFMEN1TSHRKMT2A | |
| SCHEMBL13196024 | 0.85 | RAF1 (0.43) | RAF1BRAFMEN1TSHRKMT2A | |
| SCHEMBL3139870 | 0.83 | MEN1 (0.48) | RAF1BRAFMEN1TSHRKMT2A | |
| SCHEMBL26200096 | 0.81 | NPC1 (0.51) | MEN1TSHRKMT2ANPC1RAB9A | |
| SCHEMBL25964378 | 0.78 | MEN1 (0.55) | MEN1TSHRKMT2ATK1POLB | |
| SCHEMBL14548981 | 0.77 | MEN1 (0.42) | MEN1TSHRKMT2ATK1 | |
| SCHEMBL28472801 | 0.76 | ROCK2 (0.47) | RAF1BRAFMEN1KMT2ANPC1 | |
| SCHEMBL18349588 | 0.75 | KDM4E (0.46) | MEN1TSHRKMT2ATK1SMN1; SMN2 | |
| SCHEMBL3132950 | 0.75 | MEN1 (0.46) | MEN1TSHRKMT2ATK1 | |
| SCHEMBL26200092 | 0.75 | MEN1 (0.42) | MEN1TSHRKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | FANCI, PCNA, DNMT1 | RAF1 4187/4885BRAF 2595/4885MEN1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.